Table 2.

Patient characteristics (n = 13)

CharacteristicsValue (%)
Median age at diagnosis6.4 years (1.9–13.4 years)
Median time from diagnosis to entry38 months (12.8–72.3 months)
Sex
 Male5 (38%)
 Female8 (62%)
Disease status
 Recurrent10 (77%)
 Primary refractory1 (8%)
 Partial responders2 (15%)
Stage at diagnosis
 31 (8%)
 412 (92%)
MYCN-amplified2 (15%)
Prior therapies
 Myeloablative therapy12 (92%)
 Radiation12 (92%)
 Anti-GD2 mAb9 (69%)
 Median number of prior chemotherapy regimens3 (1–10)
Disease involvement at study entry
 Bone marrow7 (54%)
 Bone11 (85%)
 mIBG avid13 (100%)
 Measureable disease10 (77%)
 Median Curie score6 (range, 1–27)
  • NOTE: Primary refractory includes progression of disease during induction chemotherapy; partial responders include patients who experienced a partial response to their primary treatment but continued to have active disease on therapy.

  • Abbreviation: mIBG, metaiodobenzylguandine.